Beta-2-Glycoprotein-I Deficiency Could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients With Coronavirus Disease 2019.


Journal

ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 19 12 2020
accepted: 09 02 2021
pubmed: 20 3 2021
medline: 20 3 2021
entrez: 19 3 2021
Statut: ppublish

Résumé

Patients with coronavirus disease 2019 (COVID-19) present coagulation abnormalities and thromboembolic events that resemble antiphospholipid syndrome (APS). This work has aimed to study the prevalence of APS-related antigens, antibodies, and immune complexes in patients with COVID-19 and their association with clinical events. A prospective study was conducted on 474 adults with severe acute respiratory syndrome coronavirus 2 infection hospitalized in two Spanish university hospitals. Patients were evaluated for classic and extra-criteria antiphospholipid antibodies (aPLs), immunoglobulin G (IgG)/immunoglobulin M (IgM) anticardiolipin, IgG/IgM/immunoglobulin A (IgA) anti-β2-glicoprotein-I (aβ2GPI), IgG/IgM antiphosphatidylserine/prothrombin (aPS/PT), the immune complex of IgA aβ2GPI (IgA-aβ2GPI), bounded to β2-glicoprotein-1 (β2GPI) and β2GPI levels soon after COVID-19 diagnosis and were followed-up until medical discharge or death. Prevalence of aPLs in patients with COVID-19 was as follows: classic aPLs, 5.8%; aPS/PT, 4.6%; IgA-aβ2GPI, 15%; and any aPL, 21%. When patients were compared with individuals of a control group of a similar age, the only significant difference found was the higher prevalence of IgA-aβ2GPI (odds ratio: 2.31; 95% confidence interval: 1.16-4.09). No significant differences were observed in survival, thrombosis, or ventilatory failure in aPL-positive versus aPL-negative patients. β2GPI median levels were much lower in patients with COVID-19 (15.9 mg/l) than in blood donors (168.8 mg/l; P < 0.001). Only 3.5% of patients with COVID-19 had normal levels of β2GPI (>85 mg/l). Low levels of β2GPI were significantly associated with ventilatory failure (P = 0.026). β2GPI levels were much lower in patients with COVID-19 than in healthy people. Low β2GPI-levels were associated with ventilatory failure. No differences were observed in the COVID-19 evolution between aPL-positive and aPL-negative patients. Functional β2GPI deficiency could trigger a clinical process similar to that seen in APS but in the absence of aPLs.

Identifiants

pubmed: 33738987
doi: 10.1002/acr2.11245
pmc: PMC8063141
doi:

Types de publication

Journal Article

Langues

eng

Pagination

267-276

Subventions

Organisme : Institute of Health Carlos III. Spanish Ministry of Economy and Competitiveness co-funded with European Regional Development Fund.
ID : PI17/00147
Organisme : Institute of Health Carlos III. Spanish Ministry of Economy and Competitiveness co-funded with European Regional Development Fund.
ID : PI17/01129

Investigateurs

Alex Almuedo (A)
Luz Bravo-Gallego (L)
Daniel Camprubí (D)
Júlia Calvo (J)
Aina Capdevila-Reniu (A)
Irene Carbonell (I)
Georgina Espígol-Frigolé (G)
Irene Fuertes (I)
Cristina Gabara (C)
Priscila Giavedoni (P)
Ignacio Grafia (I)
Andrea Ladino (A)
Gema María Lledó-Ibáñez (GM)
Ana Matas-García (A)
Pere Millat (P)
Pedro Juan Moreno (PJ)
Magdalena Muelas (M)
José Muñoz (J)
José Naval (J)
Joan Padrosa (J)
Martina Pellicé (M)
María Jesús Pinazo (MJ)
Roberto Ríos-Garcés (R)
Natalia Rodríguez (N)
Olga Rodríguez-Núñez (O)
Ruth Sotil (R)
Adrià Tomé (A)
Helena Ventosa (H)
Carles Zamora-Martínez (C)
Luis Allende (L)
Estíbaliz Arrieta (E)
Oscar Cabrera-Marante (O)
Cristina de la Calle (C)
María José Castro (MJ)
Dolores Folgueira (D)
Ana García-Reyne (A)
Rocío Laguna (R)
Elena Ana López (EA)
Jaime Lora-Tamayo (J)
Carlos Lumbreras (C)
Guillermo Maestro-de la Calle (G)
Esther Mancebo (E)
Mikel Mancheño-Losa (M)
Álvaro Marchán-López (Á)
Borja de Miguel-Campo (B)
Pablo Morales (P)
Estela Paz-Artal (E)
Daniel Pleguezuelo (D)
Edgard Rodríguez (E)
Paloma Talayero (P)

Informations de copyright

© 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Références

Front Immunol. 2019 Dec 23;10:2891
pubmed: 31921152
EMBO J. 1999 Oct 1;18(19):5166-74
pubmed: 10508150
J Intern Med. 2020 Dec;288(6):737-739
pubmed: 32506640
Front Immunol. 2018 Mar 12;9:468
pubmed: 29593726
Front Immunol. 2017 Sep 25;8:1188
pubmed: 28993777
Circ Res. 2011 May 13;108(10):1284-97
pubmed: 21566224
Antibodies (Basel). 2019 Dec 05;8(4):
pubmed: 31817406
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
SAGE Open Med Case Rep. 2020 Oct 8;8:2050313X20964089
pubmed: 33101686
Front Immunol. 2017 Dec 04;8:1708
pubmed: 29255465
Nat Rev Rheumatol. 2011 Jun;7(6):330-9
pubmed: 21556027
Blood. 2018 Jul 26;132(4):452-455
pubmed: 29784640
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Lupus. 2018 Feb;27(2):177-178
pubmed: 29067871
Blood Rev. 2020 Jan;39:100610
pubmed: 31471128
Thromb J. 2019 Aug 14;17:16
pubmed: 31423111
J Clin Med. 2020 May 31;9(6):
pubmed: 32486469
Crit Care. 2020 Jun 15;24(1):341
pubmed: 32539745
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Biochim Biophys Acta. 1986 Oct 29;884(1):142-9
pubmed: 3768409
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Biol Chem. 2008 Feb 15;283(7):3761-6
pubmed: 18073216
Transfus Apher Sci. 2020 Dec;59(6):102993
pubmed: 33162341
BMJ. 2020 Feb 18;368:m641
pubmed: 32071063
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Blood. 1997 Jun 15;89(12):4378-84
pubmed: 9192761
Blood. 1997 Apr 1;89(7):2429-42
pubmed: 9116287
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
J Thromb Haemost. 2013 Sep;11(9):1773-5
pubmed: 23742235
Br J Haematol. 2020 Aug;190(4):e181-e183
pubmed: 32453903
PLoS One. 2015 Oct 26;10(10):e0140900
pubmed: 26502286
Nat Rev Rheumatol. 2017 Sep;13(9):548-560
pubmed: 28769114
Int J Infect Dis. 2020 Oct;99:214-218
pubmed: 32585284
J Clin Virol. 2020 Jun;127:104362
pubmed: 32305883
Arq Bras Cardiol. 2011 Apr;96(4):272-6
pubmed: 21359485
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Postgrad Med. 2020 Nov;132(8):749-755
pubmed: 32573311
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Sci Transl Med. 2020 Nov 18;12(570):
pubmed: 33139519
J Thromb Haemost. 2014 Oct;12(10):1616-25
pubmed: 25081279
Int J Lab Hematol. 2016 Oct;38(5):560-8
pubmed: 27435259
J Immunol Methods. 2015 Jul;422:51-8
pubmed: 25865263
Lupus. 2006;15(2):87-93
pubmed: 16539279
Curr Med Sci. 2018 Apr;38(2):379-385
pubmed: 30074200
J Heart Lung Transplant. 2017 Nov;36(11):1258-1265
pubmed: 28579112
Autoimmunity. 2013 Aug;46(5):302-6
pubmed: 23713583
J Hepatol. 2014 Oct;61(4):770-6
pubmed: 24905490
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
J Immunol Res. 2014;2014:704395
pubmed: 24741618
Arthritis Rheum. 2013 Dec;65(12):3186-93
pubmed: 23983008
Circulation. 2017 May 16;135(20):1922-1934
pubmed: 28249878

Auteurs

Manuel Serrano (M)

Hospital 12 de Octubre, Healthcare Research Institute and Hospital Clínico San Carlos, Madrid, Spain.

Gerard Espinosa (G)

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.

Antonio Lalueza (A)

Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.

Luz Yadira Bravo-Gallego (LY)

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.

Raquel Diaz-Simón (R)

Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.

Sara Garcinuño (S)

Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.

Javier Gil-Etayo (J)

Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.

Jorge Moises (J)

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.

Laura Naranjo (L)

Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.

Sergio Prieto-González (S)

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.

Estibaliz Ruiz-Ortiz (E)

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.

Beatriz Sánchez (B)

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.

Ana Belen Moreno-Castaño (AB)

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.

Carmen Díaz-Pedroche (C)

Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.

Odette Viñas-Gomis (O)

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.

Ricard Cervera (R)

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.

Antonio Serrano (A)

Hospital 12 de Octubre, Healthcare Research Institute and Biomedical Research Centre Network for Epidemiology and Public Health, Madrid, Spain.

Classifications MeSH